Description
Biosimilars in the Belgian health care plan
Article: Biosimilars in the Belgian health care plan
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in squamous cell carcinoma of the head and neck
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart
